GlassScriptPhysician profile
Antoinette B Ferry
NPI 1669724688
$19,155.24
in general payments reported to CMS, 2019-2025
22 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $346 · 2023: $325 · 2024: $688 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $4,601 · Food and Beverage: $2,227 · Travel and Lodging: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,080.00 |
| Consulting Fee | $4,601.00 |
| Food and Beverage | $2,227.13 |
| Travel and Lodging | $1,651.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17,166.66 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $619.00 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.94 | 2021-2025 | |
| Amgen INC. | $120.00 | 2024 | Evenity |
| Millicent US INC | $111.98 | 2023-2025 | Femlyv, Intrarosa, Femring |
| Medtronic, INC. | $109.97 | 2024 | Closurefast |
| Novo Nordisk INC | $105.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $100.00 | 2021 | |
| Abbvie INC. | $85.31 | 2022-2023 | |
| Exeltis, USA INC. | $81.82 | 2022-2025 | Slynd |
| Agile Therapeutics, INC. | $78.14 | 2021-2022 | |
| Exact Sciences Corporation | $63.84 | 2025 | The Cologuard Plus Collection Kit |
| Evofem Biosciences, INC. | $62.13 | 2021-2023 | Phexxi |
| Organon LLC | $58.87 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $55.86 | 2023-2025 | Accrufer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $47.28 | 2023-2025 | Myosure Tissue Removal Device, Aptima |
| Abiomed | $36.03 | 2024 | Impella |
| Therapeuticsmd, INC. | $32.22 | 2021-2022 | |
| Coopersurgical, INC. | $30.50 | 2021-2025 | Paragard T 380a |
| Mycovia Pharmaceuticals, INC. | $20.72 | 2023 | Vivjoa |
| Merck Sharp & Dohme LLC | $19.17 | 2021 | |
| Smith+Nephew, INC. | $17.31 | 2025 | Pico 14, "Acticoat 4"" X 4""" |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoinette Ferry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.